{
    "root": "2dedbadd-050f-4a2e-9425-837bdef7632b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "JAYPIRCA",
    "value": "20250219",
    "ingredients": [
        {
            "name": "pirtobrutinib",
            "code": "JNA39I7ZVB"
        },
        {
            "name": "hypromellose acetate succinate 12070923 (3 MPA.S)",
            "code": "36BGF0E889"
        },
        {
            "name": "microcrystalline cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "croscarmellose sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "silicon dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "hypromellose, unspecified",
            "code": "3NXW29V3WO"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "triacetin",
            "code": "XHX3C3X673"
        },
        {
            "name": "FD&C BLUE No. 2 Aluminum Lake",
            "code": "4AQJ3LG584"
        }
    ],
    "indications": "JAYPIRCA ® is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",
    "contraindications": "Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. ( 2.1 ) Manage toxicity using treatment interruption, dosage reduction, or discontinuation. ( 2.2 ) Reduce dose in patients with severe renal impairment. ( 2.3 , 8.6 )",
    "warningsAndPrecautions": "How Supplied\n                  \n                  JAYPIRCA tablets are supplied as follows:\n\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Tablet Strength\n                           \n                           \n                              Description\n                           \n                           \n                              Package Configuration\n                           \n                           \n                              NDC Number\n                           \n                        \n                        \n                           50 mg\n\n                           Blue, film coated, arc-triangle shaped tablets debossed with “Lilly 50” on one side and “6902” on the other side.\n\n                           Bottle with child-resistant closure.Each bottle contains 30 tablets.\n\n                           0002-6902-30\n\n                        \n                        \n                           100 mg\n\n                           Blue, film coated, round tablets debossed with “Lilly 100” on one side and “7026” on the other side.\n\n                           Bottle with child-resistant closure.Each bottle contains 60 tablets.\n\n                           0002-7026-60\n\n                        \n                     \n                  \n                  \n                     Storage and Handling\n                  \n                  Store JAYPIRCA tablets at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) ([see USP Controlled Room Temperature]).",
    "adverseReactions": "None."
}